A carregar...
Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
The development of imatinib has revolutionized the treatment of chronic myeloid leukemia. Follow-up analysis of IRIS trial participants continues to demonstrate durable responses for imatinib at 400 mg/day. However, 10%–15% of patients with chronic myeloid leukemia will become imatinib-resistant or...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3085241/ https://ncbi.nlm.nih.gov/pubmed/21556318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMR.S11948 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|